1,685 results match your criteria Paronychia


Tubiechong:A review on ethnomedicinal uses, bioactive chemical constituents and pharmacological activities.

J Ethnopharmacol 2022 Aug 13;298:115642. Epub 2022 Aug 13.

Department of Biopharmaceuticals, School of Life Science, Beijing University of Chinese Medicine, Beijing, 100029, China. Electronic address:

Ethnopharmacological Relevance: Tubiechong comprises mainly Eupolyphaga and Steleophaga is widely distributed in China. It has been used in the traditional medicine systems in Asian countries specially in China,Japan and Singapore for thousand years.

Aim Of The Review: The aim of this work is to review the scientific work about Tubiechong regarding their ethnomedicinal uses, bioactive chemical constituents and pharmacological activities. Read More

View Article and Full-Text PDF

A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Immunopharmacol Immunotoxicol 2022 Aug 18:1-9. Epub 2022 Aug 18.

Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.

Aim: Cetuximab and panitumumab are common antibodies against epidermal growth factor receptor (EGFR) that can be used in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). Although these two drugs are considered to be very similar, differences in the efficacy and safety of cetuximab and panitumumab are still unclear. We conducted this meta-analysis to explore the effects and adverse reactions of cetuximab and panitumumab in the treatment of mCRC. Read More

View Article and Full-Text PDF

Reconstruction With a 3D-Printed Megaprosthesis With Ankle Arthrodesis After Distal Tibial Tumor Resection.

Foot Ankle Int 2022 Aug 5:10711007221115188. Epub 2022 Aug 5.

Musculoskeletal Tumor Center, Peking University People's Hospital, Xicheng District, Beijing, China.

Background: Reconstruction after en bloc resection of the distal tibia has remained an unsettled issue despite many attempts with bone grafts or prostheses in the past. Failures of the previous methods have been attributed to inadequate mechanical strength, poor articular stability, failed osseointegration, and poor soft tissue coverage. To overcome these shortcomings, we designed and applied a 3D-printed megaprosthesis with ankle arthrodesis. Read More

View Article and Full-Text PDF

[Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].

Zhongguo Fei Ai Za Zhi 2022 Jul;25(7):493-500

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), 
Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Background: Epidermal growth factor receptor (EGFR) and cellular-mesenchymal to epithelial transition factor (c-Met) are widely expressed on cancer cells. There is a synergistic effect of EGFR and HGF/c-Met pathways on proliferation, downstream activation of signal transduction and an additive effect. Studies show that combination of both signaling pathways could potentially be targeted in a synergistic fashion. Read More

View Article and Full-Text PDF

Insights on the etiopathogenesis of onychomycosis by dermatophyte, yeast and non-dermatophyte mould in ex vivo model.

Exp Dermatol 2022 Jul 12. Epub 2022 Jul 12.

Departamento de Análises Clínicas e Biomedicina, Centro de Ciências da Saúde, Universidade Estadual de Maringá (UEM), Maringá, Puerto Rico, Brazil.

Fungal biofilms have been involved in the pathogenesis of onychomycosis, but the aspects contributing to this association need to be enlightened. This study aimed to investigate the ability of three different fungi to form biofilm on the nail. All evaluated fungi were able to grow on the nails, using them as the only nutritional source and formed a structure strongly suggestive of biofilms. Read More

View Article and Full-Text PDF

A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer.

Sci Rep 2022 Jul 7;12(1):11575. Epub 2022 Jul 7.

The Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, Scotland.

Onycholysis and paronychia has been associated with chemotherapy treatment for women with breast cancer. Our primary aim was to investigate the effectiveness of different topical interventions to ameliorate nail toxicity. Secondary aims were to explore the full range and severity of possible nail changes associated with taxane-based chemotherapy and the specific impact this had on quality of life, using two novel measures. Read More

View Article and Full-Text PDF

Hair and Nail Conditions: Nail Conditions.

Authors:
Julie E Mervak

FP Essent 2022 Jun;517:27-34

Department of Dermatology - University of Michigan School of Medicine, 1910 Taubman Center 1500 E. Medical Center Drive, Ann Arbor, MI 48109-5314.

A thorough understanding of nail anatomy can help physicians identify the causes of nail conditions. Observation of changes to the nail can help establish a diagnosis. Patient evaluation should include a physical examination, dermoscopy, and, in some cases, nail biopsy. Read More

View Article and Full-Text PDF

A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer.

Expert Opin Investig Drugs 2022 Jul 3;31(7):747-757. Epub 2022 Jun 3.

Department of Medicine, UCSD Moores Cancer Center, La Jolla, CA, USA.

Introduction: This Phase 1/2 study (NCT02349633) explored the safety and antitumor activity of PF-06747775 (oral, third-generation epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer after progression on an EGFR inhibitor.

Methods: Phase 1 was a dose-escalation study of PF-06747775 monotherapy (starting dose: 25 mg once daily [QD]). Phase 1b/2 evaluated PF-06747775 monotherapy at recommended Phase 2 dose (RP2D; Cohort 1); PF-06747775 200 mg QD plus palbociclib (starting dose: 100 mg QD orally; Cohort 2A); and PF-06747775 monotherapy at RP2D in a Japanese lead-in cohort. Read More

View Article and Full-Text PDF

Acute and Chronic Paronychia Revisited: A Narrative Review.

J Cutan Aesthet Surg 2022 Jan-Mar;15(1):1-16

Department of Dermatology, Maulana Azad Medical College, Delhi, India.

Paronychia refers to the inflammation of the tissue which immediately surrounds the nail and it can be acute (<6 weeks duration) or chronic (>6 weeks duration). Disruption of the protective barrier between the nail plate and the adjacent nail fold preceded by infectious or noninfectious etiologies results in the development of paronychia. A combination of general protective measures, and medical and/or surgical interventions are required for management. Read More

View Article and Full-Text PDF

Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.

Ann Pharmacother 2022 Jun 2:10600280221098398. Epub 2022 Jun 2.

Franciscan Health Indianapolis, Indianapolis, IN, USA.

Objective: To evaluate clinical data regarding the use of amivantamab and mobocertinib for epidermal growth factor receptor (EGFR) exon 20 insertion mutation non-small cell lung cancer (NSCLC) and assess their potential impact on the care of patients.

Data Sources: A comprehensive literature search of PubMed and Clinicaltrials.gov was conducted using the terms , , , , ,

Study Selection And Data Extraction: Relevant English-language clinical trials were evaluated. Read More

View Article and Full-Text PDF

Case Study: Soft tissue infection with .

JPRAS Open 2022 Sep 1;33:17-20. Epub 2022 May 1.

is a rare encapsulated Gram-negative aerobic and facultative anaerobic rod belonging to the Enterobacteriaceae family. It tends to inhabit water and soil environments and can be found on insects, fish, ticks, and termites, but can also found in the hospital environment. has been documented in respiratory, urinary, gastrointestinal, and biliary tract infections as well as bacteraemia and systemic infections but has rarely been documented in soft tissue infections. Read More

View Article and Full-Text PDF
September 2022

Acrometastasis of Laryngeal Carcinoma to the Finger.

J Coll Physicians Surg Pak 2022 Apr;32(4):S55-S57

Department of Pathology, Diskapi Yildirim Beyazit, Training and Research Hospital, Ankara, Turkey.

Distant metastasis of laryngeal carcinoma occurs at the rate of 4%-12%, with the most common sites being the lungs, liver and bone. Acrometastasis occurs rarely in cases of laryngeal carcinoma; to date, only three cases of acrometastasis have been reported. Herein, we describe a 66-year male, who was followed up for metastatic laryngeal carcinoma and developed paronychia. Read More

View Article and Full-Text PDF

Paediatric paronychia: A single centre retrospective, microbiological analysis and national survey.

J Plast Reconstr Aesthet Surg 2022 07 22;75(7):2387-2440. Epub 2022 Apr 22.

St George's University Hospitals NHS Foundation Trust, Blackshaw Road, London, SW17 0QT, UK.

View Article and Full-Text PDF

Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment.

Dermatol Ther (Heidelb) 2022 May 4;12(5):1281-1286. Epub 2022 May 4.

Department of Dermatology, College of Medicine, Chungbuk National University, Chungdae-ro 1, Seowon-Gu, Cheongju, Chungbuk, 28644, South Korea.

Erlotinib (Tarceva) is a drug used for the treatment of non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations. Since EGFR is expressed in the skin, EGFR inhibitors commonly develop cutaneous side effects such as acneiform eruption, paronychia, telangiectasias, and abnormal eyelash growth. A 56-year-old man and a 46-year-old man visited the dermatology clinic complaining of yellowish papuloplaques and acneiform eruption on the face. Read More

View Article and Full-Text PDF

Two novel oxetane containing lignans and a new megastigmane from and analysis of them as prospective SARS-CoV-2 inhibitors.

RSC Adv 2021 Jun 4;11(33):20151-20163. Epub 2021 Jun 4.

Chemistry of Medicinal Plants Department, National Research Centre 33 El-Bohouth St., Dokki Giza 12622 Egypt +20-233370931 +20-233371635.

The chemical characterization of the extract of the aerial parts of afforded two oxetane containing lignans, paronychiarabicine A (1) and B (2), and one new megastigmane, paronychiarabicastigmane A (3), alongside a known lignan (4), eight known phenolic compounds (5-12), one known elemene sesquiterpene (13) and one steroid glycoside (14). The chemical structures of the isolated compounds were constructed based upon the HRMS, 1D, and 2D-NMR results. The absolute configurations were established NOESY experiments as well as experimental and TDDFT-calculated electronic circular dichroism (ECD). Read More

View Article and Full-Text PDF

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).

Lung Cancer 2022 06 12;168:38-45. Epub 2022 Apr 12.

Department of Medical Oncology, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.

Introduction: Alternation of osimertinib and afatinib is a potential approach to overcome osimertinib resistance and to allow complementation of drug efficacy without compromising safety in patients with epidermal growth factor receptor gene (EGFR)-mutated non-small cell lung cancer (NSCLC).

Methods: Treatment-naive patients with stage IV NSCLC harboring an activating EGFR mutation (L858R or exon-19 deletion) were enrolled. Alternating cycles of osimertinib at 80 mg/day for 8 weeks followed by afatinib at 20 mg/day for 8 weeks were administered. Read More

View Article and Full-Text PDF

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).

Thorac Cancer 2022 05 12;13(10):1471-1478. Epub 2022 Apr 12.

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Background: Dacomitinib is the second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC). EGFR-TKIs are often re-administered in Japan after the disease progression prior EGFR-TKI. There is little evidence of dacomitinib in rechallenge setting. Read More

View Article and Full-Text PDF

Nails Involvement in Winiwarter-Buerger Disease.

Skin Appendage Disord 2022 Mar 21;8(2):142-145. Epub 2021 Sep 21.

Department of Specialized, Experimental and Diagnostic Medicine, Dermatology-IRCCS, Policlinico Sant'Orsola, Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Introduction: Buerger disease, or thromboangiitis obliterans, is an inflammatory and occlusive process involving small and medium size arteries and veins, which generally affects the lower limbs of young adult male with the habit of smoking.

Case Presentation: This paper reports 2 patients who developed nail lesions as the first sign of Buerger disease.

Conclusion: Signs and symptoms of Buerger's disease are secondary to the inflammatory process and arterial occlusion which results in severe ischemia. Read More

View Article and Full-Text PDF

Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.

Chem Biol Interact 2022 May 24;358:109901. Epub 2022 Mar 24.

Department of Biotechnology, Chaudhary Devi Lal University, Sirsa, Haryana, India.

The phytochemicals contribute to the processes of protection and interaction by acting as antioxidants, anti-mutagens, anticarcinogens, and antimicrobial agents. Among the diverse families of phytoconstituents, alkaloids play an essential role in medicine. These are low-molecular-mass compounds containing nitrogen and are generally alkaline. Read More

View Article and Full-Text PDF

Kinesiology tapes wrapping for paronychia induced by epidermal growth factor receptor inhibitors: A pilot study.

Dermatol Ther 2022 Jun 29;35(6):e15463. Epub 2022 Mar 29.

Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung City, Taiwan.

View Article and Full-Text PDF

Efficacy and safety profile of Selumetinib in symptomatic inoperable plexiform neurofibromas: a systematic review and meta-analysis.

J Neurosurg Sci 2022 Mar 17. Epub 2022 Mar 17.

Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Introduction: Selumetinib is a MEK inhibitor, which is effective with an acceptable safety profile in reducing the volume of symptomatic inoperable plexiform neurofibromas in some clinical trials and also has been recently approved by FDA for use in children aged 2 years or older. However, no systematic review has yet been performed to provide a collective estimate of the results of all these trials.

Evidence Acquisition: Articles describing the use of selumetinib in patients with neurofibromatosis type-1 (NF1) with inoperable plexiform neurofibromas were searched from different electronic databases. Read More

View Article and Full-Text PDF

Metabolic complete tumor response in a patient with mutant non-small cell lung cancer treated with a reduced dose of afatinib.

J Int Med Res 2022 Mar;50(3):3000605211058864

Medical Oncology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.

Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are the first-line treatment for -mutant non-small cell lung cancer. Toxicities related to EGFR-TKIs include skin rash, paronychia, and diarrhea, which in some cases can lead to dose reductions or treatment interruptions. Herein, we report the case of a 51-year-old woman affected by advanced adenocarcinoma harboring an exon 19 deletion in the gene, who was treated with second-generation EGFR-TKI following a scheduled gradual dose reduction to better manage toxicities. Read More

View Article and Full-Text PDF

Optimal diagnosis and management of common nail disorders.

Ann Med 2022 12;54(1):694-712

Department of Dermatology, Weill Cornell Medicine New York, NY, USA.

Nail conditions are not only aesthetic concerns, and nail changes may be a clue to an underlying systemic diseases or infection. Without timely treatment, nail diseases can continue to worsen and significantly impair performance of daily activities and reduce quality of life. Examination of the nails is essential at every medical visit, and may uncover important findings. Read More

View Article and Full-Text PDF
December 2022

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.

Front Oncol 2022 10;12:804212. Epub 2022 Feb 10.

Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China.

Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancers such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer. Adverse reactions such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypomagnesemia, stomatitis, and diarrhea may occur during treatment. Because the EGFR signaling pathway is important for maintaining normal physiological skin function. Read More

View Article and Full-Text PDF
February 2022

Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes.

Exp Dermatol 2022 Jun 11;31(6):918-927. Epub 2022 Feb 11.

Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.

Epidermal growth factor receptor inhibitors (EGFRIs) are widely used for treating various cancers, including lung, colon, head and neck cancers. However, EGFRIs have unique dermatological side effects, including acneiform eruption, dry skin, paronychia and pruritus. In this study, we investigated the molecular changes induced by an EGFRI, gefitinib, in the expression of lipogenic enzymes and hyaluronic acid (HA) regulatory proteins in HaCaT keratinocytes, and whether EGF restored these changes. Read More

View Article and Full-Text PDF

Bleeding with gastrointestinal and ureteral ulcers after gefitinib treatment: a case report.

Transl Cancer Res 2021 Apr;10(4):1941-1946

Department of Respiratory and Critical Care Medicine, the Fourth Affiliated Hospital Zhejiang University School of Medicine, Yiwu, China.

Epidermal growth factor receptor (EGFR) inhibitors, as a first-line drug treatment in the EGFR-sensitive mutation of advanced non-small-cell lung cancer (NSCLC), has been used in a wide variety of malignancies. These therapies have various troublesome side effects including diarrhea, stomatitis, mucositis, rash, dry skin and paronychia which may impact a patient's clinical outcome in addition to their beneficial effects. Here, we report a rare case of a 69-year-old male having advanced NCSLC treated with gefitinib, who developed EGFR tyrosine kinase inhibitor (TKI)-related multiple ulcers accompanied by bleeding. Read More

View Article and Full-Text PDF

Gefitinib induced Pemphigus Vulgaris with PRIDE complex.

J Oncol Pharm Pract 2022 Sep 1;28(6):1465-1473. Epub 2022 Feb 1.

Department of Pharmacy Practice, 58890KLE College of Pharmacy, A Constituent Unit of KLE Academy of Higher Education and Research (KAHER), Belagavi, Karnataka, India.

Pemphigus Vulgaris is a rare, noncommunicable, non-hereditary fatal autoimmune dermatological manifestation in which a painful blister initiates from the oral cavity. PRIDE complex stands for Papulopustules or paronychia, regulatory abnormality of hair and nails, itching, and dryness due to inhibition of EGFR. Both of these mucocutaneous manifestations are rare and are often caused by drugs. Read More

View Article and Full-Text PDF
September 2022

[Prevention and treatment of mucocutaneous adverse reactions associated with epidermal growth factor receptor inhibitors].

Authors:
L Jiang K Xiao H Long

Zhonghua Yu Fang Yi Xue Za Zhi 2022 Jan;56(1):87-94

Department of Dermatology, the Second Xiangya Hospital of Central South University, Institute of Dermatology and Venereology of Central South University, Hunan Clinical Medicine Research Center for Major Skin Diseases and Skin Health, Changsha 410011, China.

The epidermal growth factor receptor (EGFR) signaling is aberrantly overexpressed in many solid malignancies, making it an important target for anti-cancer biologic agents. Among them, epidermal growth factor receptor inhibitors (EGFRIs), which have been widely used in clinical practice, include anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors. A proportion of patients treated with EGFRIs develop specific, dose-dependent skin toxicity such as papulopustular rash, paronychia, xerosis and itch. Read More

View Article and Full-Text PDF
January 2022

Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.

Clin Cancer Res 2022 04;28(8):1560-1571

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.

Purpose: EGFR pathway inhibition may promote anti-programmed cell death protein 1 (PD-1) responses in preclinical models, but how EGFR inhibition affects tumor antigen presentation during anti-PD-1 monotherapy in humans remain unknown. We hypothesized that afatinib, an irreversible EGFR tyrosine kinase inhibitor, would improve outcomes in patients treated with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) by promoting antigen presentation and immune activation in the tumor microenvironment.

Patients And Methods: The ALPHA study (NCT03695510) was a single-arm, Phase II study with Simon's 2-stage design. Read More

View Article and Full-Text PDF